anticancer/atrophy

All patients will receive usual care including: - Chemotherapy at the investigator's choice, - Outpatient clinical visits according to the regular schedule, - Tumor evaluation based on tumor marker serum levels, as appropriate, and TAP-CT with intravenous contrast injection every 8

This is a phase II pilot study to evaluate the efficacy and safety of osimertinib with bevacizumab for LM from EGFRm NSCLC patients. ALL patients were treated with Osimertinib 80mg oral daily and bevacizumab 7.5mg/kg intravenous every 3 weeks. Study therapy continued until disease progression,

The experimental group and the control group were administered until the disease progression assessed by the RECIST V1.1 standard (unless The investigator evaluates that the subject continues to have clinical benefits, and the subject can be allowed to continue receiving treatment), start new

Both study drugs will continue to be administered as long as patient experience clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status

1. COVID-19 has a high infection rate and mortality, and serious complications such as heart injury cannot be ignored. At present, the scale and harm of COVID 19 (Novel coronavirus pneumonia (NCP) has far surpassed that of SARS in 2003, with more than 80,000 cases confirmed in China and 3,119 deaths

Epidemiology and suggested mechanisms involved in pediatric chemotherapy induced neuropathy: Pediatric chemotherapy induced peripheral neuropathy (CIPN) is an early (often occurring within the first three months), potentially severe long-lasting and dose limiting adverse effect of treatment in

The World Health Organization (W.H.O). defines oral potentially malignant disorders (OPMDs) as "A histologically proven lesion that is associated with a significantly increased risk of malignant transformation."Oral leukoplakia is the most commonly occurring oral potentially malignant disorder.

This study is a single arm, single center, non randomized, open label study. It is estimated that 56 patients with advanced HCC who can not receive radical resection will be enrolled. The trial period of subjects includes screening period, treatment period and follow-up period. The drug treatment

Patients receive nivolumab and ipilimumab. Nivolumab 3 mg/kg will be given on Day 1 (± 3 days) of each 28-day treatment cycle. Ipilimumab 1 mg/kg will be given only on day 1 in cycle 1. Nivolumab will be administered as an IV infusion over 30 (± 5) minutes and then, after a 30 minutes rest period,

In 2006, the World Health Organization provided a definition of sexual health stating that "for sexual health to be reached and maintained, the sexual rights of all persons must be respected and fulfilled". Sexual quality of life is now an admitted and relevant parameter of global health and global

The current standard of care for advanced (AJCC-7 edition stage III and IV) oropharyngeal squamous cell carcinoma are concomitant chemoradiation, or surgery followed by adjuvant radiation therapy with or without concomitant chemotherapy. These approaches have persistent and significant lifelong side

Systemic anticancer treatments, whether they are conventional molecules or more current molecules such as targeted therapies, are responsible for numerous dermatological adverse effects, notably xerosis, the repercussions of which may lead to a decrease in compliance, dose reductions or even a

The purpose of this study is to evaluate the effectiveness of our new method for high dose partial irradiation of the hypoxic tumor segment of bulky masses in terms of the intentional induction of the non-targeted effects of radiotherapy in patients with metastatic or locally advanced (N+)

Despite the mortality rates among cancer patients have been greatly reduced as a result of medical advances in cancer screening and treatment in recent decades, cancer itself and the adverse effects of treatment are still threatening to young cancer patients, with vast destruction in both physical